ISPC

iSpecimen Inc

ISPC, USA

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

https://ispecimen.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ISPC
stock
ISPC

Weekly Trades: What is the dividend yield of ISPC - 2025 Technical Patterns & Smart Allocation Stock Tips baoquankhu1.vn

Read more →
ISPC
stock
ISPC

iSpecimen completes private placement, engages IR consulting firm MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$3

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.59

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-90.49 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-30.90 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,847.87 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.93

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.04% of the total shares of iSpecimen Inc

1.

Citadel Advisors Llc

(0.237%)

since

2025/06/30

2.

Geode Capital Management, LLC

(0.1804%)

since

2025/06/30

3.

UBS Group AG

(0.1709%)

since

2025/06/30

4.

XTX Topco Ltd

(0.1228%)

since

2025/06/30

5.

Fidelity Extended Market Index

(0.0778%)

since

2025/07/31

6.

Tower Research Capital LLC

(0.0753%)

since

2025/06/30

7.

Fidelity Series Total Market Index

(0.0666%)

since

2025/07/31

8.

BlackRock Inc

(0.0344%)

since

2025/06/30

9.

Fidelity Nasdaq Composite Index

(0.0217%)

since

2025/07/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0151%)

since

2025/07/31

11.

Fidelity Total Market Index

(0.0143%)

since

2025/07/31

12.

NT Ext Equity Mkt Idx Fd - L

(0.0044%)

since

2025/06/30

13.

Northern Trust Extended Eq Market Idx

(0.0044%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - NL

(0.004%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0031%)

since

2025/06/30

16.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0012%)

since

2025/06/30

17.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.001%)

since

2024/12/31

18.

State St US Extended Mkt Indx NL Cl C

(0.0006%)

since

2025/08/31

19.

Bank of America Corp

(0.0003%)

since

2025/06/30

20.

SSgA U.S. Total Market Index Strategy

(0.0003%)

since

2025/03/31

21.

SBI Securities Co Ltd

(0.0001%)

since

2025/06/30

22.

Sachetta LLC

(0%)

since

2025/06/30

23.

Bridgeway Capital Management, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.48

EPS Estimate

0

EPS Difference

-0.48

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(4)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.